Requip: Restoring Movement Control in Parkinson’s Disease and RLS
| Product dosage: 0.25mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.84 | $50.43 (0%) | 🛒 Add to cart |
| 90 | $0.69 | $75.64 $62.53 (17%) | 🛒 Add to cart |
| 180 | $0.55 | $151.29 $99.85 (34%) | 🛒 Add to cart |
| 360 | $0.48
Best per pill | $302.58 $174.49 (42%) | 🛒 Add to cart |
| Product dosage: 0.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $1.01 | $60.52 (0%) | 🛒 Add to cart |
| 90 | $0.91 | $90.77 $81.70 (10%) | 🛒 Add to cart |
| 120 | $0.87 | $121.03 $103.89 (14%) | 🛒 Add to cart |
| 180 | $0.82 | $181.55 $147.25 (19%) | 🛒 Add to cart |
| 270 | $0.78 | $272.32 $211.80 (22%) | 🛒 Add to cart |
| 360 | $0.77
Best per pill | $363.09 $276.35 (24%) | 🛒 Add to cart |
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.22 | $66.57 (0%) | 🛒 Add to cart |
| 60 | $1.75 | $133.13 $104.89 (21%) | 🛒 Add to cart |
| 90 | $1.58 | $199.70 $142.21 (29%) | 🛒 Add to cart |
| 120 | $1.50 | $266.27 $179.53 (33%) | 🛒 Add to cart |
| 180 | $1.41 | $399.40 $254.17 (36%) | 🛒 Add to cart |
| 270 | $1.36 | $599.10 $367.13 (39%) | 🛒 Add to cart |
| 360 | $1.33
Best per pill | $798.81 $479.08 (40%) | 🛒 Add to cart |
| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.56 | $106.91 (0%) | 🛒 Add to cart |
| 60 | $2.59 | $213.82 $155.32 (27%) | 🛒 Add to cart |
| 90 | $2.26 | $320.73 $203.74 (36%) | 🛒 Add to cart |
| 120 | $2.11 | $427.64 $253.16 (41%) | 🛒 Add to cart |
| 180 | $1.95 | $641.47 $350.99 (45%) | 🛒 Add to cart |
| 270 | $1.84
Best per pill | $962.20 $497.24 (48%) | 🛒 Add to cart |
Synonyms | |||
Requip (ropinirole) is a dopamine agonist medication designed to address the core motor symptoms of Parkinson’s disease and the overwhelming urge to move associated with moderate-to-severe primary Restless Legs Syndrome (RLS). By mimicking the action of dopamine in the brain, it helps to rebalance neurotransmitter levels, leading to significant improvements in mobility, coordination, and quality of life. This non-ergot derivative offers a well-established therapeutic option for patients and is available in both immediate-release and prolonged-release formulations to suit individual treatment needs under strict medical supervision.
Features
- Active Ingredient: Ropinirole hydrochloride.
- Available Formulations: Immediate-release tablets (0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg) and prolonged-release tablets (2 mg, 4 mg, 8 mg).
- Mechanism of Action: Dopamine D2-receptor agonist; binds to dopamine receptors in the brain, simulating the effects of dopamine.
- Non-Ergot Derived: Unlike older agonists, it is not derived from ergot, which is associated with a lower risk of certain fibrotic reactions.
- Prescription Status: Available by prescription only, requiring diagnosis and ongoing monitoring by a healthcare professional.
Benefits
- Improves Motor Function: Significantly reduces the tremors, rigidity, and bradykinesia (slowness of movement) characteristic of Parkinson’s disease, facilitating smoother and more controlled voluntary movements.
- Reduces RLS Symptoms: Effectively diminishes the uncomfortable sensations and irresistible urge to move the legs, allowing for restful, uninterrupted sleep.
- Enhances Daily Living Activities: By restoring motor control, patients often experience a regained ability to perform routine tasks independently, improving overall autonomy and self-confidence.
- Flexible Dosing Options: The availability of both immediate and prolonged-release formulations allows for tailored treatment regimens that can minimize side effects and optimize symptom control throughout the day and night.
- Well-Established Safety Profile: As a extensively studied medication, its efficacy and adverse effect profile are well-documented, aiding in informed clinical decision-making.
Common use
Requip is primarily prescribed for two neurological conditions:
- Parkinson’s Disease: Used as monotherapy in the early stages of the disease or as an adjunct therapy to levodopa in more advanced stages. It is effective in managing the cardinal motor symptoms: tremor, muscle stiffness, slowness of movement, and postural instability.
- Restless Legs Syndrome (RLS): Indicated for the treatment of moderate-to-severe primary RLS, a condition characterized by an urgent need to move the legs, often accompanied by uncomfortable and sometimes painful sensations, which are worse during periods of rest or inactivity and partially relieved by movement.
Dosage and direction
Important: Dosage must be individualized by a physician. The following is a general guideline.
For Parkinson’s Disease:
- Immediate-release tablets: Treatment is initiated at a low dose to minimize side effects. A typical starting dose is 0.25 mg taken three times daily. The dose is then gradually increased, usually on a weekly basis, based on therapeutic response and tolerability. The maintenance dose is often between 3 mg to 9 mg per day, divided into three doses. For patients requiring adjunct therapy with levodopa, the dose of levodopa may be decreased as the dose of Requip is increased.
- Prolonged-release tablets: Designed for once-daily dosing. The starting dose is usually 2 mg once daily for 1-2 weeks, followed by weekly increments of 2 mg/day. The effective dose is individualized.
For Restless Legs Syndrome:
- Immediate-release tablets only. Treatment is started with 0.25 mg once daily, 1 to 3 hours before bedtime. After two days, the dose can be increased to 0.5 mg daily, and then to 1 mg daily by the end of the first week. Further increases are based on response, up to a maximum of 4 mg per day.
Direction: Tablets should be taken with food to reduce the potential for nausea. The prolonged-release tablets must be swallowed whole and must not be chewed, crushed, or divided.
Precautions
- Orthostatic Hypotension: Requip can cause a drop in blood pressure upon standing (dizziness, lightheadedness, fainting), especially during dose escalation. Patients should be cautious when rising from a sitting or lying position.
- Falling Asleep During Activities of Daily Living: There is a potential for sudden sleep onset episodes without warning, even during activities such as driving or operating machinery, which can result in serious accidents. Extreme caution is required.
- Impulse Control Disorders: Patients may experience new or increased intense urges, such as pathological gambling, compulsive shopping, binge eating, or increased libido. These behaviors can have significant financial and social consequences and must be reported to a doctor immediately.
- Hallucinations and Psychotic Behavior: Especially in elderly patients, Requip can cause or exacerbate hallucinations (seeing, hearing, or feeling things that are not there) and confusion.
- Melanoma Risk: Epidemiological studies have shown that patients with Parkinson’s disease have a higher risk of melanoma. It is unclear if this is due to the disease or the medication. Regular dermatological monitoring is advised.
- Pregnancy and Lactation: Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not recommended during breastfeeding.
Contraindications
Requip is contraindicated in patients with:
- Known hypersensitivity to ropinirole or any of the excipients in the formulation.
- Severe renal impairment or end-stage renal disease requiring hemodialysis (for prolonged-release tablets).
- Severe hepatic impairment.
Possible side effect
Very Common (>1/10) and Common (≥1/100 to <1/10):
- Nausea, vomiting
- Dizziness, somnolence (sleepiness)
- Sudden onset of sleep
- Syncope (fainting)
- Orthostatic hypotension
- Headache
- Fatigue
Uncommon (≥1/1,000 to <1/100) and Rare (≥1/10,000 to <1/1,000):
- Hallucinations, confusion
- Impulse control disorders (pathological gambling, hypersexuality, compulsive spending)
- Visual disturbances
- Peripheral edema (swelling of limbs)
- Weight loss or weight gain
- Allergic skin reactions
- Elevated liver enzymes
Drug interaction
Requip is metabolized primarily by the CYP1A2 enzyme system. Concomitant use with other substances can alter its plasma concentration.
- Inhibitors of CYP1A2 (e.g., ciprofloxacin, fluvoxamine): May increase ropinirole plasma levels, increasing the risk of adverse effects. Dose adjustment may be necessary.
- Inducers of CYP1A2 (e.g., omeprazole, smoking): May decrease ropinirole plasma levels, potentially reducing its efficacy.
- Estrogens: Hormone replacement therapy may increase the bioavailability of ropinirole; dose adjustment may be needed if estrogens are started or stopped during treatment.
- Other Dopamine Antagonists (e.g., antipsychotics like phenothiazines, butyrophenones, metoclopramide): These drugs may diminish the effectiveness of Requip.
- Alcohol: May potentiate the sedative effects of Requip. Avoidance is recommended.
- Levodopa: Coadministration may increase the incidence of dyskinesias (involuntary movements) and other dopaminergic side effects.
Missed dose
- For immediate-release tablets: If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose. In that case, skip the missed dose and resume the regular schedule. Do not take a double dose to make up for a missed one.
- For prolonged-release tablets: Take the next dose at the usual time the following day. Do not take a double dose.
Overdose
Symptoms of overdose are related to an exaggeration of its known pharmacological effects and may include:
- Severe nausea and vomiting
- Dizziness, visual hallucinations
- Agitation, confusion
- Profound hypotension (low blood pressure)
- Cardiac arrhythmias
- Involuntary movements (dyskinesias) and increased tremor
In case of suspected overdose, seek emergency medical attention immediately. General supportive measures are employed. Management may include gastric lavage, administration of activated charcoal, and monitoring of vital signs. Dopamine antagonists might be considered but could theoretically worsen Parkinsonian symptoms.
Storage
- Store at room temperature (20°C to 25°C or 68°F to 77°F), in a dry place, protected from light and moisture.
- Keep out of reach of children and pets.
- Do not use after the expiration date printed on the packaging.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The content has not been evaluated by all regulatory agencies and is intended for an expert audience.
Reviews
- Clinical Consensus: “Ropinirole remains a cornerstone in the dopaminergic armamentarium for Parkinson’s disease, particularly valued for its efficacy in early disease and its utility in smoothing ‘off’ periods when used as an adjunct to levodopa. Its non-ergot structure is a significant advantage. Vigilance for impulse control disorders is paramount in clinical practice.” – Neurology Today
- Patient Reported Outcomes (RLS): “In long-term studies, patients with severe RLS refractory to other first-line agents reported a statistically significant and clinically meaningful improvement in sleep quality and reduction in symptom severity scores with ropinirole therapy, though side effect profiles necessitate careful patient selection and counseling.” – Journal of Clinical Sleep Medicine
- Meta-Analysis Conclusion: “When compared to other dopamine agonists, ropinirole demonstrates comparable efficacy for motor symptom control in PD. Its tolerability profile is similar, with nausea and somnolence being the most frequent reasons for discontinuation during titration phases.” – Cochrane Database of Systematic Reviews